Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Orion Office REIT Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.08 (market cap $2.86B), while Orion Office REIT Inc trades at $2.11 (market cap $119.79M). The key difference: Dyne Therapeutics Inc. Common Stock is far larger — about 23.9× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 3.81% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Orion Office REIT Inc for 34 Days on average.
| DYN | ONL | |
|---|---|---|
Market Cap | $2.86B | $119.79M |
Volume | 3,341,579 | 378,596 |
Sector | Health | Real Estate |
52-Week High | $26.78 | $3.00 |
52-Week Low | $14.60 | $1.93 |
Typical Hold Time | 0 Days | 34 Days |
Enterprise Value | $2.18B | $536.73M |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
ONL trades at $2.10, down 2.33% today, with a bearish technical signal from moving averages. The company shows declining revenue from $208M in 2022 to $148M in 2025 and persistent net losses, though Q2 2026 EPS beat expectations. Valuation metrics appear mixed with low P/S (0.84) and P/B (0.19) ratios but negative profitability margins. Analyst consensus is evenly split between Buy and Hold ratings.
The outlook remains challenging due to ongoing revenue declines and negative margins, though the deep discount to book value and recent earnings beat offer potential upside. Key risks include high debt levels, weak office property demand, and sustained cash flow pressures. Investors should weigh the value proposition against fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
